Reversing resistance to targeted therapy

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Molecular targeted anticancer drugs represent a significant advancement in cancer treatment.
• Drug resistance to these novel therapies is a major clinical obstacle, limiting their long-term efficacy.

Purpose of the Study:

• To identify and categorize common molecular mechanisms underlying drug resistance to targeted anticancer agents.
• To highlight the importance of molecular evaluation in understanding and overcoming therapeutic resistance.

Main Methods:

• Review and synthesis of existing literature on molecular targeted drug resistance.
• Categorization of resistance mechanisms based on molecular alterations at various biological levels (DNA, mRNA, protein).
• Emphasis on the role of pharmacokinetics, pharmacogenetics, and pharmacodynamics in resistance.

Main Results:

• Common resistance mechanisms include inadequate target blockade, altered target expression or structure, modified target regulation, and activation of alternative signaling pathways.
• Specific examples of targeted agents like hormone therapies, trastuzumab, imatinib, and gefitinib illustrate these mechanisms.
• Drug resistance is often multifactorial, involving complex molecular interactions.

Conclusions:

• A comprehensive molecular understanding of drug resistance is crucial for developing effective reversal strategies.
• Integrating pharmacokinetic, pharmacogenetic, and pharmacodynamic studies will facilitate improved patient outcomes in targeted cancer therapy.
• Future research should focus on personalized approaches to combatting molecular resistance in cancer treatment.